COMPANY Data
Companies by Sector
More than 6000 listed
My FAVORITES
Movers and SHAKERS
TherapeuticsMD Announces Submission of Low Dose BIJUVA Supplemental New Drug Application to FDA

TherapeuticsMD Announces Submission of Low Dose BIJUVA® 0.5 mg/100 mg Supplemental New Drug Application to FDA

 

BOCA RATON, Fla.--(BUSINESS WIRE)--May 25, 2021--  TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative, leading women’s healthcare company, announced today that the Company submitted a supplemental New Drug Application (“sNDA”) for BIJUVA (estradiol and progesterone) capsules, 0.5 mg/100 mg, to the  U.S. Food and Drug Administration (“FDA”).

The Company expects to learn of the acceptance of the sNDA upon receipt of the Filing Review Notification from the FDA, approximately 74 days after submission. If accepted, the Company expects that the review time under the Prescription Drug User Fee Act (PDUFA) will be within ten months of receipt by the FDA, approximately  March 21, 2022.

“We are pleased to have identified a path forward for submission to the FDA of our sNDA for low-dose BIJUVA. We believe low-dose BIJUVA will be an important additional therapeutic option for women, if approved, and we look forward to bringing it to market,” said  Robert G. Finizio, Chief Executive Officer of  TherapeuticsMD.

BIJUVA is the only FDA-approved bio-identical hormone therapy combination of estradiol and progesterone in a single, oral capsule. It is taken once-daily for the treatment of moderate to severe vasomotor symptoms (commonly known as hot flashes or flushes) due to menopause in women with a uterus.

About BIJUVA

BIJUVA is a novel combination of bio-identical estradiol and bio-identical progesterone in a once-daily oral softgel capsule. BIJUVA is approved in the  U.S. in a 1mg/100mg strength for the treatment of moderate to severe vasomotor symptoms due to menopause in women with a uterus.

INDICATION

BIJUVA (estradiol and progesterone) is a combination of an estrogen and progesterone indicated in a woman with a uterus for the treatment of moderate to severe vasomotor symptoms due to menopause.

IMPORTANT SAFETY INFORMATION

WARNING: CARDIOVASCULAR DISORDERS, BREAST CANCER, ENDOMETRIAL CANCER, and PROBABLE DEMENTIA

See full prescribing information for complete boxed warning.

Estrogen Plus Progestin Therapy

  • Estrogen plus progestin therapy should not be used for the prevention of cardiovascular disease or dementia
  • The Women’s Health Initiative (WHI) estrogen plus progestin substudy reported increased risks of stroke, deep vein thrombosis (DVT), pulmonary embolism (PE), and myocardial infarction (MI)
  • The WHI estrogen plus progestin substudy reported increased risks of invasive breast cancer
  • The WHI Memory Study (WHIMS) estrogen plus progestin ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

Estrogen-Alone Therapy

  • There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens
  • Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia
  • The WHI estrogen-alone substudy reported increased risks of stroke and DVT
  • The WHIMS estrogen-alone ancillary study of WHI reported an increased risk of probable dementia in postmenopausal women 65 years of age and older

CONTRAINDICATIONS

BIJUVA is contraindicated in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast; known or suspected estrogen-dependent neoplasia; active DVT, PE, or history of these conditions; active arterial thromboembolic disease (for example, stroke, MI), or a history of these conditions; known anaphylactic reaction, angioedema, or hypersensitivity to BIJUVA or any of its ingredients; known liver impairment or disease; known protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders.

WARNINGS AND PRECAUTIONS

  • An increased risk of PE, DVT, stroke, and MI has been reported with estrogen plus progestin therapy. Should these occur or be suspected, therapy should be discontinued immediately. Risk factors for arterial vascular disease and/or venous thromboembolism (VTE) should be managed appropriately.
  • The WHI substudy of daily estrogen plus progestin after a mean follow-up of 5.6 years reported an increased risk of invasive breast cancer. Observational studies have also reported an increased risk of breast cancer for estrogen plus progestin therapy after several years of use. The risk increased with duration of use and appeared to return to baseline over about 5 years after stopping treatment (only the observational studies have substantial data on risk after stopping). The use of estrogen plus progestin therapy has been reported to result in an increase in abnormal mammograms requiring further evaluation.
  • Endometrial hyperplasia (a possible precursor to endometrial cancer) has been reported to occur at a rate of approximately less than one percent with BIJUVA. Clinical surveillance of all women using estrogen plus progestin therapy is important. Adequate diagnostic measures should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
  • The WHI estrogen plus progestin substudy reported a statistically non-significant increased risk of ovarian cancer. A meta-analysis of 17 prospective and 35 retrospective epidemiology studies found that women who used hormonal therapy for menopausal symptoms had an increased risk for ovarian cancer. The exact duration of hormone therapy use associated with an increased risk of ovarian cancer, however, is unknown.
  • In the WHIMS ancillary studies of postmenopausal women 65 to 79 years of age, there was an increased risk of developing probable dementia in women receiving estrogen plus progestin when compared to placebo. It is unknown whether these findings apply to younger postmenopausal women.
  • Estrogens increase the risk of gallbladder disease.
  • Discontinue estrogen if severe hypercalcemia, loss of vision, severe hypertriglyceridemia, or cholestatic jaundice occurs.
  • Monitor thyroid function in women on thyroid replacement hormone therapy.

The most common adverse reactions (?3%) for BIJUVA are breast tenderness (10.4%), headache (3.4%), vaginal bleeding (3.4%), vaginal discharge (3.4%) and pelvic pain (3.1%).

Please note that this information is not comprehensive. Please see the Full Prescribing Information including BOXED WARNING at BIJUVA.com.

About TherapeuticsMD, Inc.

TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The company is committed to advancing the health of women and championing awareness of their healthcare issues. To learn more about  TherapeuticsMD, please visit therapeuticsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook:  TherapeuticsMD.

Forward-Looking Statements

This press release by  TherapeuticsMD, Inc. may contain forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to TherapeuticsMD’s objectives, plans and strategies as well as statements, other than historical facts, that address activities, events or developments that the company intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in this press release are made as of the date of this press release, and the company undertakes no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of the company’s control. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections titled "Risk Factors" in the company’s filings with the  Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as reports on Form 8-K, and include the following: whether the FDA will accept and approve the NDA efficacy supplement for the lower dose of BIJUVA; the effects of the COVID-19 pandemic; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and commercialize IMVEXXY®, ANNOVERA®, and BIJUVA® and obtain additional financing necessary therefor; whether the company will be able to comply with the covenants and conditions under its term loan facility; whether the company will be able to successfully divest its vitaCare business and how the proceeds that may be generated by any such divestiture will be utilized; the potential of adverse side effects or other safety risks that could adversely affect the commercialization of the company’s current or future approved products or preclude the approval of the company’s future drug candidates; the company’s ability to protect its intellectual property, including with respect to the Paragraph IV notice letters the company received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s reliance on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to commercialize and distribute the company’s products; the ability of the company’s marketing contractors to market ANNOVERA; the availability of reimbursement from government authorities and health insurance companies for the company’s products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the trading price of the company’s common stock and the concentration of power in its stock ownership.

Investor Contacts
Nichol Ochsner
Vice President, Investor Relations
561-961-1900, ext. 2088
Nochsner@TherapeuticsMD.com

In-Site Communications, Inc.
Lisa M. Wilson
212-452-2793
lwilson@insitecony.com

Media Contact
Kristen Landon
Vice President,  Marketing and Corporate Communications
561-961-1900
Klandon@therapeuticsmd.com

Source:  TherapeuticsMD, Inc.



Company Ticker Price Previous Mkt Cap Volume 52wk Range
TherapeuticsMD Inc.
TXMD (NGS)
$1.24
$1.22 (+1.80%)
$488.34M
0
$1.00 - $2.75
Fundamental Analysis
Rating Refer to Research Report
NEWS Channel
No News
RESEARCH Reports
No News
ChannelCast VIDEOS
Company
Title
Salem Media Group Inc.
C-Suite Interview
Helius Medical Technologies Inc.
C-Suite Interview
Great Bear Resources Ltd - New
C-Suite Interview
Medicine Man Technologies Inc
Virtual Roadshow Replay
Energy Services of America Corp.
Fireside Chat Replay
Genprex Inc.
C-Suite Interview
Stem Holdings Inc
C-Suite Interview
Ayala Pharmaceuticals Inc.
Virtual Roadshow Replay
PDS Biotechnology Corporation
C-Suite Interview
Chakana Copper Corp - Ordinary Shares
C-Suite Interview
Bassett Furniture Industries Incorporated
C-Suite Interview
eSports Entertainment Group Inc
C-Suite Interview
PDS Biotechnology Corporation
Virtual Roadshow Replay
Palladium One Mining Inc
Virtual Roadshow Replay
Golden Predator Mining Corp
C-Suite Interview
Energy Fuels Inc
C-Suite Interview
enCore Energy Corp
Virtual Roadshow Replay
Medicine Man Technologies Inc
C-Suite Interview
Ayala Pharmaceuticals Inc.
C-Suite Interview
Capstone Green Energy
Virtual Roadshow Replay
eSports Entertainment Group Inc
Virtual Roadshow Replay
Allegiant Gold Ltd
Virtual Roadshow Replay
enCore Energy Corp
C-Suite Interview
Palladium One Mining Inc
C-Suite Interview
Comstock Mining Inc.
C-Suite Interview
Capstone Green Energy
C-Suite Interview
Allegiant Gold Ltd
C-Suite Interview
1-800 FLOWERS.COM Inc.
Fireside Chat
Kelly Services Inc. Class A Common Stock
C-Suite Interview
Acco Brands Corporation
Virtual Road Show
FAT Brands Inc.
Virtual Road Show
Palladium One Mining Inc
Virtual Road Show
Ayala Pharmaceuticals Inc.
C-Suite Interview
Neovasc Inc.
Virtual Road Show
Aurania Resources
Virtual Road Show
Lineage Cell Therapeutics, Inc.
Virtual Road Show
InPlay Oil
Virtual Road Show
One Stop Systems Inc.
Virtual Road Show
Pangaea Logistics Solutions Ltd.
C-Suite Interview
Palladium One Mining Inc
C-Suite Interview
Genco Shipping & Trading Limited New (Marshall Islands)
C-Suite Interview
Kratos Defense & Security Solutions Inc.
C-Suite Interview
Lineage Cell Therapeutics, Inc.
C-Suite Interview
E.W. Scripps Company (The)
C-Suite Interview
Dyadic International Inc.
Virtual Road Show
PDS Biotechnology Corporation
Virtual Road Show
Comstock Mining Inc.
Virtual Road Show
Vectrus Inc.
C-Suite Interview
Energy Fuels Inc
Virtual Road Show
Gray Television Inc.
C-Suite Interview
Coeur Mining Inc.
C-Suite Interview
Gevo Inc.
Virtual Road Show
InPlay Oil
C-Suite Interview
Genprex Inc.
Virtual Road Show
Comstock Mining Inc.
C-Suite Interview
Eagle Bulk Shipping Inc.
C-Suite Interview
CoreCivic Inc.
Virtual Road Show
Entravision Communications Corporation
C-Suite Interview
Golden Predator Mining Corp
Virtual Road Show
PDS Biotechnology Corporation
C-Suite Interview
electroCore Inc.
C-Suite Interview
Energy Fuels Inc
C-Suite Interview
FAT Brands Inc.
C-Suite Interview
Acco Brands Corporation
C-Suite Interview
Newrange Gold Corp.
Virtual Road Show
CoreCivic Inc.
C-Suite Interview
Golden Predator Mining Corp
C-Suite Interview
Sierra Metals Inc.
Virtual Road Show
Genprex Inc.
C-Suite Interview
One Stop Systems Inc.
C-Suite Interview
DLH Holdings Corp.
Virtual Road Show
Seanergy Maritime Holdings Corp
C-Suite Interview
Great Lakes Dredge & Dock Corporation
Virtual Road Show
Indonesia Energy Corp Ltd - Ordinary Shares
Virtual Road Show
Neovasc Inc.
C-Suite Interview
Sierra Metals Inc.
C-Suite Interview
Aurania Resources
C-Suite Interview
Dyadic International Inc.
C-Suite Interview
Ely Gold Royalties Inc - Ordinary Shares
Virtual Road Show
Onconova Therapeutics Inc.
C-Suite Interview
Newrange Gold Corp.
C-Suite Interview
Energy Services of America Corp.
C-Suite Interview
Orion Group Holdings Inc. Common
C-Suite Interview
Indonesia Energy Corp Ltd - Ordinary Shares
C-Suite Interview
Great Lakes Dredge & Dock Corporation
C-Suite Interview
Gevo Inc.
C-Suite Interview
1-800 FLOWERS.COM Inc.
C-Suite Interview
Ely Gold Royalties Inc.
C-Suite Interview
Tonix Pharmaceuticals Holding Corp.
NobleCon16
AgEagle Aerial Systems Inc.
NobleCon16
Duos Technologies Group Inc
NobleCon16
Progressive Care Inc
NobleCon16
Xenetic Biosciences Inc.
NobleCon16
Comstock Mining Inc.
NobleCon16
Caladrius Biosciences Inc.
NobleCon16
PDS Biotechnology Corporation
NobleCon16
Newrange Gold Corp.
NobleCon16
Cocrystal Pharma Inc.
NobleCon16
Empire Diversified Energy Inc
NobleCon16
Sierra Metals Inc.
NobleCon16
Abacus Health Products Inc.
NobleCon16
Energy Fuels Inc
NobleCon16
InPlay Oil Corp.
NobleCon16
Assure Holdings
NobleCon16
Pyxis Tankers Inc.
NobleCon16
Comtech Telecommunications Corp.
NobleCon16
Ballard Power Systems Inc.
NobleCon16
Capstone Green Energy
NobleCon16
Hoth Therapeutics Inc.
NobleCon16
Avino Silver & Gold Mines Ltd. (Canada)
NobleCon16
Lightwave Logic Inc
NobleCon16
Orion Group Holdings Inc. Common
NobleCon16
Pangaea Logistics Solutions Ltd.
NobleCon16
Summit Wireless Technologies Inc.
NobleCon16
Sernova Corp
NobleCon16
Gray Television Inc.
NobleCon16
Sundance Energy Inc. - Ordinary Shares
NobleCon16
Exactus Inc
NobleCon16
Cornerstone Capital Resources Inc.
NobleCon16
Gevo Inc.
NobleCon16
OncoSec Medical Incorporated
NobleCon16
Lineage Cell Therapeutics, Inc.
NobleCon16
ProMIS Neurosciences Inc.
NobleCon16
SRAX
NobleCon16
Euroseas Ltd.
NobleCon16
Tower One Wireless Corp
NobleCon16
EuroDry Ltd.
NobleCon16
Genprex Inc.
NobleCon16
Eagle Bulk Shipping Inc.
NobleCon16
Freedom Holding Corp - Ordinary Shares
NobleCon16
Dyadic International Inc.
NobleCon16
1-800 FLOWERS.COM Inc.
NobleCon16
International Seaways Inc.
NobleCon16
Helix Biopharma Corp
NobleCon16
Matinas Biopharma Holdings Inc.
NobleCon16
Endeavour Silver Corporation (Canada)
NobleCon16
Educational Development Corporation
NobleCon16
Entravision Communications Corporation
NobleCon16
Brainstorm Cell Therapeutics Inc.
NobleCon16
Interpace Diagnostics Group Inc.
NobleCon16
Ely Gold Royalties Inc.
NobleCon16
Lumina Gold Corp.
NobleCon16
Information Services Group Inc.
NobleCon16
Ceapro Inc
NobleCon16
Cardiff Oncology Inc.
NobleCon16
Qualstar Corporation
NobleCon16
Great Panther Mining Limited (Canada)
NobleCon16
Salem Media Group Inc.
NobleCon16
Acco Brands Corporation
NobleCon16
Citius Pharmaceuticals Inc.
NobleCon16
Golden Valley Mines Ltd
NobleCon16
Silver One Resources Inc.
NobleCon16
Seanergy Maritime Holdings Corp
NobleCon16
Kelly Services Inc. Class A Common Stock
NobleCon16
Onconova Therapeutics Inc.
NobleCon16
Ocugen, Inc.
NobleCon16
Imagin Medical Inc
NobleCon16
Exro Technologies Inc - Ordinary Shares
NobleCon16
Indonesia Energy Corp Ltd - Ordinary Shares
NobleCon16
Salarius Pharmaceuticals
NobleCon16
SPI Energy Co. Ltd.
NobleCon16
Ely Gold Royalties Inc - Ordinary Shares
NobleCon16
Tribune Publishing Company
NobleCon16
electroCore Inc.
NobleCon16
Applied Energetics Inc
NobleCon16
Aeterna Zentaris Inc.
NobleCon16
Townsquare Media Inc. Class A
2019 Radio Show: Bill Wilson Opening
Enochian Biosciences Inc.
Introduction
Actinium Pharmaceuticals Inc. (Delaware)
Actinium Pharmaceuticals at NobleConXV
QuoteMedia Inc.
NobleCon XV
Aurania Resources Ltd.
NobleConXV
Information Services Group Inc.
NobleConXV
Salem Media Group Inc.
NobleConXV
The KEYW Holding Corporation
NobleConXV
Townsquare Media Inc. Class A
NobleConXV
Tribune Publishing Company
NobleConXV
Salem Media Group Inc.
Salem Media Group at NobleCon
Cardiff Oncology Inc.
TrovaGene Inc at NobleConXV
Genie Energy Ltd. Class B Stock
NobleConXV
Pyxis Tankers Inc.
Pyxis Tankers Inc. at NobleConXV
Pangaea Logistics Solutions Ltd.
Pangaea Logistics Solutions Ltd. at NobleConXV
One Stop Systems Inc.
NobleConXV
Seanergy Maritime Holdings Corp
Seanergy Maritime Holdings at NobleConXV
Great Panther Mining Limited (Canada)
Great Panther Silver at NobleConXV
Great Lakes Dredge & Dock Corporation
Great Lakes Dredge & Dock Corporation at NobleConXV
Genco Shipping & Trading Limited New (Marshall Islands)
Genco Shipping & Trading Limited at NobleConXV
Endeavour Silver Corporation (Canada)
Endeavour Silver Corporation at NobleConXV
Eagle Bulk Shipping Inc.
Eagle Bulk Shipping at NobleConXV
Brainstorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics at NobleConXV
Dyadic International Inc.
Dyadic International at NobleConXV
Arcadia Biosciences Inc.
Arcadia Biosciences Inc at NobleConXV
Comtech Telecommunications Corp.
Comtech Telecommunications Corp. at NobleConXV
Torchlight Energy Resources Inc.
Torchlight Energy Resources, Inc. at NobleConXV
electroCore Inc.
NobleConXV
Altimmune Inc.
Altimmune Inc at NobleConXV
Sierra Metals Inc.
Sierra Metals Inc. at NobleConXV
IEC Electronics
IEC Electronics at NobleConXV